BioSyntech awarded 2007 Innovation Award from ADRIQ

    LAVAL, QC, Nov. 27 /CNW/ - BioSyntech, Inc. ("BioSyntech" or the
"Company") (TSX: BSY), a biotechnology company developing biotherapeutic
thermogels for regenerative medicine, today announced it has been awarded the
2007 Innovation Award in the "Partnership" category by the Association de la
Recherche Industrielle du Quebec (ADRIQ) for its successful partnership with
the Ecole Polytechnique de Montréal (Ecole Polytechnique). Founded in 1873,
Ecole Polytechnique is one of Canada's leading engineering institutions in
both teaching and research. The Company received the award during a ceremony
that took place in Montreal, Quebec, on November 22, 2007.
    The Partnership Award honours a company and an organization involved in a
technological partnership project which clearly demonstrates the benefits of
shared expertise. BioSyntech and Ecole Polytechnique initiated their
collaboration in 1997 to develop a family of biomaterials with the ability to
stimulate growth and regeneration of damaged tissue. The partnership has been
strengthened recently with the establishment of the BioSyntech/NSERC Chair in
Hybrid Biomaterials in April 2007, directed by Professor Michael D. Buschmann.
    "We are honored that ADRIQ has recognized the technological benefits of
our scientific collaboration with Ecole Polytechnique and our efforts to
contribute to the development of less invasive solutions for the repair of
damaged tissue," said Claude LeDuc, President and CEO of BioSyntech. "This
partnership gives us considerable access to world-class research which has
already translated to numerous approved patents and several products within
the development pipeline."

    About BioSyntech

    BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), liquid at low
temperature and solid at human body temperature. These gels can be injected or
applied to a specific local site and offer beneficial properties for the local
repair of damaged tissue such as cartilage, bone and chronic wounds and
provide the benefit of avoiding invasive surgery. The Company's two lead,
late-stage products, BST-CarGel(R) and BST-DermOn(TM), are currently
undergoing Canadian and European pivotal trials. For additional information,

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results or our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at
    These statements speak only as of the date they are made, and we assume
no obligation to revise such statements as a result of any event, circumstance
or otherwise, except in accordance with law.

    %SEDAR: 00020217EF

For further information:

For further information: BioSyntech, Inc., Yvonne Kramer, Ph.D., Sr.
Director Corporate & Business Development, (450) 686-2437, ext. 315,; Investor relations: The Equicom Group Inc., Eric
Bouchard, (514) 844-7997,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890